MX2015007753A - Composicion de vacunas para sujetos intactos. - Google Patents

Composicion de vacunas para sujetos intactos.

Info

Publication number
MX2015007753A
MX2015007753A MX2015007753A MX2015007753A MX2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A MX 2015007753 A MX2015007753 A MX 2015007753A
Authority
MX
Mexico
Prior art keywords
vaccine
vaccine composition
subjects
naive subjects
directed
Prior art date
Application number
MX2015007753A
Other languages
English (en)
Spanish (es)
Inventor
Hans Arwidsson
Anna-Karin Maltais
Original Assignee
Eurocine Vaccines Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Vaccines Ab filed Critical Eurocine Vaccines Ab
Publication of MX2015007753A publication Critical patent/MX2015007753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
MX2015007753A 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos. MX2015007753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Publications (1)

Publication Number Publication Date
MX2015007753A true MX2015007753A (es) 2016-01-08

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007753A MX2015007753A (es) 2012-12-17 2013-12-17 Composicion de vacunas para sujetos intactos.
MX2015007688A MX2015007688A (es) 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015007688A MX2015007688A (es) 2012-12-17 2013-12-17 Composicion de vacunas para uso en poblaciones inmunocomprometidas.

Country Status (12)

Country Link
US (2) US20150306204A1 (OSRAM)
EP (4) EP2742952A1 (OSRAM)
JP (3) JP2016502997A (OSRAM)
KR (3) KR20210007042A (OSRAM)
CN (3) CN112826929A (OSRAM)
AU (2) AU2013360889C1 (OSRAM)
BR (2) BR112015014174A2 (OSRAM)
CA (2) CA2895028A1 (OSRAM)
HK (2) HK1212611A1 (OSRAM)
MX (2) MX2015007753A (OSRAM)
RU (2) RU2661408C2 (OSRAM)
WO (2) WO2014095943A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298484B (zh) * 2010-09-30 2017-04-26 优若森疫苗公司 改进的疫苗组合物
EP4144369A1 (en) * 2014-09-26 2023-03-08 Seqirus UK Limited Vaccination of immunocompromised subjects
JP2017528511A (ja) 2014-09-26 2017-09-28 セキラス ユーケー リミテッド 免疫低下された被験体のワクチン接種
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
US20200306364A1 (en) * 2017-11-30 2020-10-01 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135519B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
US20230133087A1 (en) * 2020-04-16 2023-05-04 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
WO2023133342A2 (en) * 2022-01-10 2023-07-13 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
JP2004527524A (ja) 2001-04-05 2004-09-09 カイロン コーポレイション 非経口初回抗原刺激後の粘膜追加免疫
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
DK1567191T3 (da) 2002-11-26 2011-01-03 Eurocine Vaccines Ab Ny amin-baseret adjuvans
CN1867355A (zh) 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
KR101294455B1 (ko) 2005-06-30 2013-08-07 에자이 알앤드디 매니지먼트 가부시키가이샤 면역 아쥬반트 제조용 화합물
US8211442B2 (en) 2005-08-05 2012-07-03 The University Of Tokushima Mucosal vaccine enabling switching from production of IgA antibody to production of both of IgA and IgG antibodies
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
CA2725381A1 (en) 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
ES2618576T3 (es) 2009-05-28 2017-06-21 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
CN103298484B (zh) 2010-09-30 2017-04-26 优若森疫苗公司 改进的疫苗组合物

Also Published As

Publication number Publication date
EP3431101A1 (en) 2019-01-23
RU2015129028A (ru) 2017-01-23
CN112826929A (zh) 2021-05-25
AU2013360889B2 (en) 2016-12-01
AU2013360890A1 (en) 2015-07-02
JP2016502996A (ja) 2016-02-01
EP2742952A1 (en) 2014-06-18
CA2895023A1 (en) 2014-06-26
AU2013360890B2 (en) 2017-04-13
BR112015014243A2 (pt) 2017-07-11
AU2013360889C1 (en) 2017-06-08
KR20210007042A (ko) 2021-01-19
BR112015014174A2 (pt) 2017-07-11
RU2661408C2 (ru) 2018-07-16
KR20150132093A (ko) 2015-11-25
CN104884085A (zh) 2015-09-02
MX2015007688A (es) 2015-09-07
WO2014095943A1 (en) 2014-06-26
JP2019112448A (ja) 2019-07-11
BR112015014243A8 (pt) 2019-10-08
JP2016502997A (ja) 2016-02-01
EP2931308A1 (en) 2015-10-21
RU2661407C2 (ru) 2018-07-16
EP2931307B1 (en) 2018-09-12
HK1213492A1 (zh) 2016-07-08
EP2931308B1 (en) 2018-10-10
RU2015129077A (ru) 2017-01-23
CN104870010A (zh) 2015-08-26
KR20150132092A (ko) 2015-11-25
AU2013360889A1 (en) 2015-07-02
HK1212611A1 (zh) 2016-06-17
EP2931307A1 (en) 2015-10-21
US20150306205A1 (en) 2015-10-29
WO2014095944A1 (en) 2014-06-26
US20150306204A1 (en) 2015-10-29
US11065325B2 (en) 2021-07-20
CA2895028A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
MX383065B (es) Mutantes de virus de influenza y usos para los mismos.
PH12015501482A1 (en) Nasal influenza vaccine composition
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX2015010880A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
PE20151588A1 (es) Vacuna contra el virus del dengue
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201290956A1 (ru) Вакцина против вич
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
BR112015002549A2 (pt) regime de vacinação para proteger uma criança contra infecção ou doença causada por vírus sincicial respiratório, composição imunogênica ou pluralidade de composições imunogênicas, uso de uma composição imunogênica ou de uma pluralidade de composições imunogênicas
MX376962B (es) Nuevos compuestos macrociclicos.
EA033027B1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
WO2013173256A3 (en) New and improved influenza vaccines
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención
MX2015005112A (es) Composicion inmunogenica contra la aeromonas hydrophila.
BR112013023354A2 (pt) vacina para rinite equina
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
CO6511241A2 (es) Régimen de inmunizaión por sensibilización-refuerzo heteróloga